Other EZH2 inhibitors with completed clinical trials include MorphoSys' lirametostat (CPI-1205) and GSK's GSK2816126, which both reached mid-stage testing, but now appear to have been discontinued.

Daiichi Sankyo has a second approval in Japan for Ezharmia, its first-in-class dual EZH1 and EZH2 inhibitor, as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL).